Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Three For The Citi: Pfizer, Bristol, GSK Provide R&D, Pricing Briefings

Executive Summary

Pfizer’s Mikael Dolsten, Bristol’s Francis Cuss and GSK’s Andrew Witty gave updates on their companies’ progress and direction at the Citi Global Healthcare Conference. Immuno-oncology was a common thread in Dolsten and Cuss’ comments, while Witty talked about GSK’s revised pricing strategies.

You may also be interested in...

Pfizer Sets Its Sights On Therapeutic Cancer Vaccines

The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.

Pfizer Oncology: Big Strides But Not Blockbuster Size

Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.

GSK’s Witty Speaks Further On M&A, Pricing

U.K. pharma giant’s growth will come from a diversified, innovative portfolio of medicines, emerging markets, vaccines, and “bolt-ons.”


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts